Products
Clindamycin vaginal cream has been approved in many countries since 1995 (Dalacin V).
Structure and properties
Clindamycin (C18H33ClN2O5S, Mr = 425.0 g/mol) is a derivative of lincomycin (7-chloro-7-deoxy-lincomycin) obtained from. It is present in vaginal cream as clindamycin phosphate, a white, slightly hygroscopic powder that is readily soluble in water.
Effects
Clindamycin (ATC G01AA10) has bacteriostatic to bactericidal properties. It binds to the 50S subunit of bacterial ribosomes, thereby inhibiting protein synthesis.
Indications
For the treatment of bacterial vaginosis (amine colpitis, Gardnerella vaginitis) caused by susceptible pathogens.
Dosage
According to the professional information. The cream is administered vaginally at night before bedtime and for three days. If this is not sufficient, a seven-day treatment may be followed.
Contraindications
Clindamycin is contraindicated in hypersensitivity and in patients with a history of antibiotic-associated colitis. For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with lincomycin, erythromycin, and neuromuscular blocking agents.
Adverse effects
The most common potential adverse effects include local irritation, pruritus, vaginal thrush, and lower abdominal pain. Pseudomembranous colitis may develop with oral clindamycin. If diarrhea occurs, treatment should be discontinued.
Cf.
Clindamycin
